A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021)

Radiotherapy and Oncology

Volumn 92, Issue 2, 2009, Pages 260-265

  Nishimura, Yasumasa ^a   Mitsumori, Michihide ^b   Hiraoka, Masahiro ^b   Koike, Ryuta ^a   Nakamatsu, Kiyoshi ^a   Kawamura, Masashi ^c   Negoro, Yoshiharu ^d   Fujiwara, Kazuhisa ^e   Sakurai, Hideyuki ^f   Mitsuhashi, Norio ^g  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Nara Social Insurance Hospital   (Japan)

^d FUKUI PREFECTURAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

A randomized phase II study; Chemoradiotherapy; Esophageal cancer

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INFUSION; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS HEMORRHAGE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; INFECTION; INFORMED CONSENT; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEURA DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNCONSCIOUSNESS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 67650873209     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.12.012     Document Type: Article

References (15)

1. Al-Sarraf M., Herskovic A., Martz K., et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup study. J Clin Oncol 15 (1997) 277-284
2. Cooper J.S., Guo M.D., Herskovic A., and Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281 (1999) 1623-1627
3. Smith T.J., Ryan L.M., Douglass Jr. H.O., and A study of the Eastern Cooperative Oncology Group. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 42 (1998) 269-276
4. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
5. Nishimura Y., Suzuki M., Nakamatsu K., et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 53 (2002) 134-139
6. Koike R., Nishimura Y., Nakamatsu K., et al. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Int J Radiat Oncol Biol Phys 70 (2008) 1418-1422
7. Ohtsu A., Boku N., Muro K., et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 (1999) 2915-2921
8. Sakai K., Inakoshi H., Sueyama H., et al. Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 31 (1995) 921-927
9. Sai H., Mitsumori M., Yamauchi C., et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 9 (2004) 149-153
10. Hsu C., Yeh K., Lui L., et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer; a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 19 (1999) 4463-4468
11. Ishida K., Iizuka T., Ando N., et al. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese Institutions Trial. Jpn J Clin Oncol 26 (1996) 310-315
12. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep 69 (1985) 1375-1381
13. Nishimura Y. Rationale for chemoradiotherapy. Int J Clin Oncol 9 (2004) 414-420
14. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
15. Ahmed H.F., Hussain M.A., Grant C.E., et al. Closure of tracheoesophageal fistulas with chemotherapy and radiotherapy. Am J Clin Oncol 21 (1998) 177-179